Compounders just lost their case to put obesity drug tirzepatide back in shortage
Tirzepatide, compounding, FDA, drug shortage, Eli Lilly, Zepbound, Mounjaro, legal case, Outsourcing Facilities Association (OFA), GLP-1 medications
From deal to disaster: Drugmakers face a changed Washington as Trump embraces most favored nation prices
Prices, Transplant Registry Unified Management Program, MFN, Nation, Disasters, Medicaid, Policy, drugmakers, U.S.
Protect Your Trial Data: Endpoint, Imaging, and Safety Review
Clinical Trials, Diagnostic Imaging, Security – service, End Point, safety review, General Data Protection Regulation, Biomechanical compliance, CTMS, Encryption
RFK Jr. claims placebo-controlled vaccine trials are’radical departure’ from past. Experts disagree
Vaccines, placebo-controlled trials, CHARGE Syndrome, experts, Effectiveness, RFK Jr., Policy, Approved, HHS
NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader
Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases
Amid Trumps Trade War, Some Drugmakers Stockpile Products in U.S.
United States, Import, trade deficit
Trumps US Manufacturing Push, New Vaccine Policy, Novos Weight Loss Pill up for FDA Review
Policy, trade deficits, Vaccines, United States Food and Drug Administration
Beacon’s rare eye disease gene therapy signals vision function improvements in early phase 2 data
XLRP, gene therapy, laru-zova, visual function, rare eye disease, Phase 2 trial, DAWN trial, vision improvement, low light vision
Aldeyra hopes new data for dry-eye disease drug will satisfy FDA
United States Food and Drug Administration, Aldeyra, reproxalap, Approved, Dry Eye Syndromes, Clinical Trials, New Drug Application